Study of Safety, Tolerability and Clinical Outcomes of Egaten in Fascioliasis Patients (6 Years of Age or Older).

NCT04230148 | Completed Phase 4 FDA Drug

• 1 other identifier: CEGA230B2404
• Study Type: interventional
• Target: 301
• Locations: 5 countries
• Sites: 10

Brief Summary

This is a multicenter, open label, non-comparative, single arm multi-country study in approximately 300 adult and pediatric subjects (≥ 6 years of age) with fascioliasis. The study population consists of male and female adult and pediatric patients (≥ 6 years of age). The study will enroll approximately 300 subjects with acute (minimum 15% of overall study population) or chronic fascioliasis. Enrolled subjects will receive two doses of 10 mg/kg of Egaten given approximately 12 hours apart. Subjects will be treated and followed up on an outpatient basis. After screening and post treatment, at Day 3 and Day 6 the subjects will be followed for safety and tolerability. These visits are primarily for safety follow up and may be telephonic or home visit by qualified personnel or onsite visits based on the investigator's discretion. During visits Day 10, Day 30, Day 60 and Day 90 post-treatment, the subjects will be followed for safety, tolerability and efficacy. On Day 15, Day 45 and Day 75, telephonic follow-up (primarily for safety) will be conducted.

Conditions

Fascioliasis

Keywords

Acute Fascioliasis; Chronic Fascioliasis; Clinical Cure; Parasitological Cure; Egaten; Triclabendazole; Post-Marketing commitment

Outcome Measures

Primary Outcomes (1)

• Number of Participants with On-Treatments Adverse Events, Serious Adverse Events, and Deaths

  Analysis of absolute and relative frequencies for treatment emergent Adverse Event (AE), Serious Adverse Event (SAE) and Deaths by primary System Organ Class (SOC) to demonstrate that Egaten administered as two 10 mg/kg doses given 12 hours apart in subjects with Fascioliasis is safe through the monitoring of relevant clinical and laboratory safety parameters.

  Day 90

Secondary Outcomes (3)

• Clinical cure rate in Acute Fascioliasis subjects over time.

  Day 10, Day 30, Day 60 and Day 90

• Parasitological cure rate in Chronic Fascioliasis subjects over time.

  Day 10, Day 30, Day 60 and Day 90

• Clinical cure rate of Chronic Fascioliasis subjects over time.

  Day 10, Day 30, Day 60 and Day 90

Study Arms (1)

Egaten

EXPERIMENTAL

All subjects will receive Egaten as two 10 mg/kg doses given 12 hours apart.

Drug: Egaten (Triclabendazole) 250 mg tablets

Interventions

Egaten (Triclabendazole) 250 mg tablets DRUG

Egaten 250 mg scored tablets for oral use.

Also known as: Triclabendazole

Egaten

Eligibility Criteria

• Age: 6 Years - 99 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Written informed consent must be obtained before any study protocol specific assessment is performed.
• Parental/legal guardian informed consent must be obtained and signed for pediatric subjects (formally documented and witnessed, via an independent trusted witness) prior to any study related procedure.
• Subjects \< 18 years old, who are capable of providing assent, must provide assent with parental/legal guardian consent or as per local ethical guidelines.
• If the subject is unable to read and write or otherwise incapable of signing an informed consent, then a witnessed consent according to local ethical standards is permitted.
• Subjects (Adult and pediatric subjects ≥ 6 years of age and above 12.5 kg of weight) at time of consenting must have been diagnosed with fascioliasis based on clinical signs, symptoms and laboratory evaluations as per local clinical practice.

You may not qualify if:

• Subjects diagnosed with ectopic fascioliasis, extrahepatic involvement (e.g., lungs, spleen, pancreas, subcutaneous tissue, gastrointestinal organs, etc.).
• Subjects with known hypersensitivity to triclabendazole /other benzimidazole derivatives and/or any of the excipients in Egaten.
• Subjects taking any anthelmintic medications within two weeks or 5 half-lives, whichever is longer prior to enrolling into study.
• Inability or unwillingness to undergo study related procedures.
• Subjects who in the judgment of the Clinical Investigator are unsuitable for the trial or who have to be excluded in order to be compliant with local fascioliasis management guidelines that may differ from the FDA approved label, including but not limited to :
• Subjects who are machine operators or drivers.
• Medical history of liver (other than fascioliasis), kidney or cardiac disease.
• Females (including under the age of 18) known to be pregnant or testing positive for pregnancy at screening.
• Lactating women unwilling to discontinue lactation up to 72 hours after the second dose administration or as per local guidelines.
• Subjects requiring therapeutic drug monitoring of CYP2C19 substrate(s) (e.g. S-mephenytoin).
• Subjects with medical history of QT prolongation or a history of symptoms compatible with a long QT interval or on medication which prolong the QT interval.

Sponsors & Collaborators

• Novartis Pharmaceuticals: lead

Study Sites (10)

Novartis Investigative Site

Medellín, Antioquia, 050010, Colombia

Location

Novartis Investigative Site

Alexandria, 21131, Egypt

Location

Novartis Investigative Site

Cairo, 11617, Egypt

Location

Novartis Investigative Site

San Martín de Porres, Lima region, 31, Peru

Location

Novartis Investigative Site

Cusco, 84, Peru

Location

Novartis Investigative Site

Istanbul, Fatih, 34093, Turkey (Türkiye)

Location

Novartis Investigative Site

Gaziantep, Sehitkamil, 27310, Turkey (Türkiye)

Location

Novartis Investigative Site

Sur, 21280, Turkey (Türkiye)

Location

Novartis Investigative Site

Van, 65080, Turkey (Türkiye)

Location

Novartis Investigative Site

Qui Nhon, Binh Dinh, 590000, Vietnam

Location

MeSH Terms

Conditions

Fascioliasis

Interventions

Triclabendazole

Condition Hierarchy (Ancestors)

Trematode Infections; Helminthiasis; Parasitic Diseases; Infections; Liver Diseases, Parasitic; Liver Diseases; Digestive System Diseases

Intervention Hierarchy (Ancestors)

Benzimidazoles; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds

Study Officials

• Novartis Pharmaceuticals

  Novartis Pharmaceuticals

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 14, 2020
• First Posted: January 18, 2020
• Study Start: February 11, 2022
• Primary Completion: March 27, 2026
• Study Completion: March 27, 2026
• Last Updated: May 1, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will share

Locations

PE (2); EG (2); VN (1); TU (4); CO (1)